secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2021-10-26T23:59:59+00:00
Accession:  0001104659-21-129738
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.01, 5.02, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyeGate closes Bayon acquisition, issues 33,798 shares; appoints Eric Daniels as CDO
--------------------------------------------------------------------------------

- Acquired Bayon Therapeutics for 33,798 common shares; up to $7.1M in milestone payments possible.
- Eric Daniels appointed CDO with base salary AUD$492,000 and option for 50,000 shares.
- CEO Brian Strem and new CDO Eric Daniels each owned ~28% of Bayon before acquisition.
- Milestone payments tied to clinical trial data and FDA approval of Bayon product candidates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000110465921129738/0001104659-21-129738-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000110465921129738/tm2130996d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-129738

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer